Telehealth in oncology: a cost analysis to evaluate the financial impact of implementing regional trial hubs within a phase 3 cancer clinical trial

被引：3
|
作者：
Alexander, Marliese [1 ,4 ,14 ]
Collins, Ian [6 ,7 ]
Abraham, Patrick [5 ]
Underhill, Craig [12 ,13 ]
Harris, Sam [8 ]
Torres, Javier [9 ,10 ]
Sharma, Sharad [11 ]
Solomon, Benjamin [2 ,4 ]
Tran-Duy, An [5 ]
Burbury, Kate [3 ,4 ]
机构：
[1] Peter MacCallum Canc Ctr, Dept Pharm Dept, Melbourne, Australia
[2] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Australia
[3] Peter MacCallum Canc Ctr, Dept Haematol, Melbourne, Australia
[4] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Australia
[5] Univ Melbourne, Ctr Hlth Policy, Melbourne Sch Populat & Global Hlth, Melbourne, Australia
[6] Victorian Comprehens Canc Ctr, Melbourne, Australia
[7] Deakin Univ, Melbourne, Australia
[8] Bendigo Hlth, Bendigo Canc Ctr, Bendigo, Australia
[9] Goulburn Valley Hlth, Peter Copulos Canc & Wellness Ctr, Shepparton, Australia
[10] Univ Melbourne, Shepparton Clin Sch, Shepparton, Australia
[11] Grampians Hlth, Ballarat Reg Integrated Canc Ctr, Ballarat, Vic, Australia
[12] Albury Wodonga Reg Canc Ctr, Border Med Oncol & Haematol Res Unit, Albury Wodonga, Australia
[13] Univ New South Wales, Rural Med Sch, Sydney, NSW, Australia
[14] Peter MacCallum Canc Ctr, Locked Bag 1ABeckett St, Melbourne, Vic 8006, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2023年 / 53卷 / 12期
基金：
英国医学研究理事会;
关键词：
cost analysis; teletrial; patient cost; cancer; clinical trial;
D O I：
10.1111/imj.16292
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This cost analysis, from a societal perspective, compared the cost difference of a networked teletrial model (NTTM) with four regional hubs versus conventional trial operation at a single metropolitan specialist centre. The Australian phase 3 cancer interventional randomised controlled trial included 152 of 328 regional participants (patient enrolment 2018-2021; 6-month primary end point). The NTTM significantly reduced (AU$2155 per patient) patient travel cost and time and lost productivity.
引用
收藏
页码：2346 / 2349
页数：4
相关论文
共 50 条
  • [41] Improving bladder cancer outcomes: The impact of initiating a phase IV randomised controlled clinical trial
    Ray, Eleanor R.
    Coker, Bola
    Chatterton, Kathryn
    Khan, Mohamed S.
    O'Brien, Tim S.
    JOURNAL OF CLINICAL UROLOGY, 2009, 2 (02) : 67 - 72
  • [42] Evaluating the Impact of Performance Status on Outcomes in Advanced Lung Cancer: A Phase II Clinical Trial
    Porebski, M. F.
    Grant, S. C.
    Petty, W. J.
    Ruiz, J.
    Triozzi, P.
    Levine, B. J.
    Atkins, J. N.
    Khan, K.
    Soto-Pantoja, D. R.
    Lycan, T. W.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S394 - S394
  • [43] Change in financial toxicity during early-phase cancer clinical trial (EP-CT) participation
    Durbin, Sienna
    Lundquist, Debra
    Pelletier, Andrea
    Petrillo, Laura A.
    Lam, Anh B.
    Jimenez, Rachel
    Turbini, Victoria
    Bame, Viola
    Lynch, Kaitlyn
    Yalala, Vaishnavi Reddy
    Ollila, Nicholas
    Malowitz, Benjamin
    McIntyre, Casandra
    Juric, Dejan
    Nipp, Ryan David
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients
    Tate, Sonya C.
    Sykes, Amanda K.
    Kulanthaivel, Palaniappan
    Chan, Edward M.
    Turner, P. Kellie
    Cronier, Damien M.
    CLINICAL PHARMACOKINETICS, 2018, 57 (03) : 335 - 344
  • [45] Impact of age on clinical trial availability for AYAs with cancer: A time-trend analysis
    Bhutada, Jessica Sheth
    Mittal, Nupur
    Freyer, David R.
    Roth, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients
    Sonya C. Tate
    Amanda K. Sykes
    Palaniappan Kulanthaivel
    Edward M. Chan
    P. Kellie Turner
    Damien M. Cronier
    Clinical Pharmacokinetics, 2018, 57 : 335 - 344
  • [47] Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials-Application of the Estimand Framework
    Degtyarev, Evgeny
    Rufibach, Kaspar
    Shentu, Yue
    Yung, Godwin
    Casey, Michelle
    Englert, Stefan
    Liu, Feng
    Liu, Yi
    Sailer, Oliver
    Siegel, Jonathan
    Sun, Steven
    Tang, Rui
    Zhou, Jiangxiu
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2020, 12 (04): : 427 - 437
  • [48] Randomized controlled trial to evaluate the clinical- and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses
    Boland, A
    Haycox, A
    Bagust, A
    Fitzsimmons, L
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2005, 21 (01) : 145 - 146
  • [49] Filgrastim in the Treatment of Infected Diabetic Foot UlcersRetrospective Cost Analysis of a Phase II Randomised Clinical Trial
    Michael Edmonds
    Andrew Gough
    José Solovera
    Bo Standaert
    Clinical Drug Investigation, 1999, 17 : 275 - 286
  • [50] Cadherins, catenins and cell cycle regulators: Impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trial
    Singh, Meenakshi
    Darcy, Kathleen M.
    Brady, William E.
    Clubwala, Rashna
    Weber, Zachary
    Rittenbach, Jon V.
    Akalin, Ali
    Whitney, Charles W.
    Zaino, Richard
    Ramirez, Nilsa C.
    Leslie, Kimberly K.
    GYNECOLOGIC ONCOLOGY, 2011, 123 (02) : 320 - 328
12345